Literature DB >> 16118482

Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.

Tsukasa Nakamura1, Takeshi Sugaya, Isao Ebihara, Hikaru Koide.   

Abstract

BACKGROUND: Microscopic hematuria without proteinuria is a common clinical finding in cases of immunoglobulin A (IgA) nephropathy and of thin basement membrane nephropathy. Liver-type fatty acid-binding protein (L-FABP) is expressed in renal proximal tubules and is reported to be a useful marker of the progression of chronic glomerulonephritis. AIM: To assess urinary L-FABP levels for differential diagnosis in patients with microscopic hematuria but without proteinuria.
METHODS: This was a multi-center retrospective study. Thirty adult patients who underwent renal biopsy for microscopic hematuria and 20 healthy adult volunteers were included in this study. Urinary L-FABP levels were measured by enzyme-linked immunosorbent assay and compared, particularly between those diagnosed with IgA nephropathy and those diagnosed with thin basement membrane nephropathy.
RESULTS: Twelve (40%) patients had IgA nephropathy, 6 (20%) had thin basement membrane nephropathy and 12 (40%) had normal biopsy findings. The urinary L-FABP level was significantly higher in patients with IgA nephropathy (38.4 +/- 26.8 microg/g Cr) than in healthy subjects (5.8 +/- 4.0 microg/g Cr) (p < 0.01); however, the level in patients with thin basement membrane nephropathy or normal biopsy results was comparable to that in healthy subjects. Follow-up data were available for 11 of the 12 patients with IgA nephropathy who initially had no proteinuria. After 24 months, 4 of the 11 were found to have proteinuria, and the urinary L-FABP level had increased from 40.6 +/- 30.5 microg/g Cr to 58.8 +/- 40.5 microg/g Cr (p < 0.01).
CONCLUSIONS: Our data suggest that the urinary L-FABP level can be used to discriminate between IgA nephropathy and thin basement membrane nephropathy in patients with microscopic hematuria. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118482     DOI: 10.1159/000087826

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  Urinary L-FABP as a marker of vesicoureteral reflux in children: could it also have a protective effect on the kidney?

Authors:  Meryem Benzer; Sebnem Tekin Neijmann; Nazlı Dilay Gültekin; Aslı Uluturk Tekin
Journal:  Int Urol Nephrol       Date:  2016-08-22       Impact factor: 2.370

Review 2.  Biomarkers of nephrotoxic acute kidney injury.

Authors:  Michael A Ferguson; Vishal S Vaidya; Joseph V Bonventre
Journal:  Toxicology       Date:  2008-01-04       Impact factor: 4.221

3.  Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury.

Authors:  Michael A Ferguson; Vishal S Vaidya; Sushrut S Waikar; Fitz B Collings; Kelsey E Sunderland; Costas J Gioules; Joseph V Bonventre
Journal:  Kidney Int       Date:  2009-11-25       Impact factor: 10.612

Review 4.  Biomarkers of acute kidney injury.

Authors:  Vishal S Vaidya; Michael A Ferguson; Joseph V Bonventre
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 5.  Predicting acute kidney injury: current status and future challenges.

Authors:  Simona Pozzoli; Marco Simonini; Paolo Manunta
Journal:  J Nephrol       Date:  2017-06-17       Impact factor: 3.902

6.  Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes.

Authors:  Nicolae M Panduru; Carol Forsblom; Markku Saraheimo; Lena Thorn; Angelika Bierhaus; Per M Humpert; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2013-02-01       Impact factor: 19.112

7.  Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.

Authors:  Tomoyo Hara; Ryoko Uemoto; Akiko Sekine; Yukari Mitsui; Shiho Masuda; Kiyoe Kurahashi; Sumiko Yoshida; Toshiki Otoda; Tomoyuki Yuasa; Akio Kuroda; Yasumasa Ikeda; Itsuro Endo; Soichi Honda; Katsuhiko Yoshimoto; Akira Kondo; Toshiaki Tamaki; Toshio Matsumoto; Munehide Matsuhisa; Masahiro Abe; Ken-Ichi Aihara
Journal:  J Diabetes Investig       Date:  2021-06-23       Impact factor: 4.232

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.